 |
|
|
| |
Using Real World Data to Assess the Risk of Suicidality among Patients Initiating an Efavirenz versus an Efavirenz-Free Antiretroviral Regimen
|
| |
| |
Reported by Jules Levin
IDSA Oct 8-12 2014 Philadelphia, PA
Ella Nkhoma1*, John Coumbis2, Amanda Farr3, Stephen Johnston3, Bong Chul Chu3, Lisa Rosenblatt4, Daniel Seekins5, Angelina Villasis Keever5
1Bristol-Myers Squibb, Global Pharmacovigilance and Epidemiology, Wallingford, Connecticut, United States, 2Bristol-Myers Squibb, Global Pharmacovigilance and Epidemiology, Hopewell, New Jersey, United States, 3Truven Health Analytics, Bethesda, Maryland, United States, 4Bristol-Myers Squibb, Health Economics and Outcomes Research, Plainsboro, New Jersey, United States, 5Bristol-Myers Squibb, US Medical, Plainsboro, New Jersey, United States
*Disclosure for Ella Nkhoma: Employee, Bristol-Myers Squibb; no other disclosure
|
| |
|
|
|
|
|
